Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia

被引：0
|
作者：
Wysoglad, Hubert [1 ,2 ]
Krawczyk, Katarzyna [2 ,3 ]
Ochrem, Bogdan [2 ,3 ]
Madry, Krzysztof [1 ]
Drozd-Sokolowska, Joanna [1 ]
Sacha, Tomasz [2 ,3 ]
Basak, Grzegorz [1 ]
机构：
[1] Med Univ Warsaw, Dept Hematol Transplantol & Internal Med, Warsaw, Poland
[2] Univ Hosp Krakow, Dept Hematol, Krakow, Poland
[3] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
acute myeloid leukemia; azacitidine; venetoclax; real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-384
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [31] Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia
    Gibson, Amber
    Dickson, Samantha
    McCall, David
    Garcia, Miriam
    Connors, Jeremy
    He, Jiasen
    Roth, Michael
    Nunez, Cesar
    Cuglievan, Branko
    PEDIATRIC BLOOD & CANCER, 2024,
  • [32] Safety and Efficacy of Azacitidine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukemia in Arab Population: A Single-Center, Retrospective Study
    Alwadi, Mohammmad
    Howaidi, Jude
    Alrajhi, Abdullah M.
    Alnakhli, Adel
    Marei, Mohammed A.
    Tailor, Imran K.
    Alnajjar, Fouad H.
    Altaf, Syed Y.
    Alnoamani, Mohammed S.
    Alzahrani, Kamal
    Alshehri, Hassan
    Motabi, Ibraheem H.
    Zaidi, Syed Ziauddin A.
    Alshehry, Nawal F.
    Alfayez, Mansour
    BLOOD, 2021, 138
  • [33] Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance
    Burke, Mary
    Sallman, David A.
    Denson, Ariel
    Nelson, Rebecca Jean
    Chan, Onyee
    Walker, Alison R.
    Padron, Eric
    Xie, Zhuoer
    Komrokji, Rami S.
    Lancet, Jeffrey
    Kuykendall, Andrew T.
    Tobon, Katherine
    Jain, Akriti Gupta
    Wang, Chen
    Al Ali, Najla H.
    BLOOD, 2023, 142
  • [34] Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy
    Lurienne, Lise
    Le Bescop, Clement
    Buffet, Renaud
    Bandinelli, Pierre-Alain
    BLOOD, 2020, 136
  • [35] Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy
    Lurienne, Lise
    Le Bescop, Clement
    Buffet, Renaud
    Bandinelli, Pierre-Alain
    BLOOD, 2020, 136
  • [36] Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy
    Bocchia, Monica
    Candoni, Anna
    Borlenghi, Erika
    Defina, Marzia
    Fili, Carla
    Cattaneo, Chiara
    Sammartano, Vincenzo
    Fanin, Renato
    Sciume, Margherita
    Sicuranza, Anna
    Imbergamo, Silvia
    Riva, Marta
    Fracchiolla, Nicola
    Latagliata, Roberto
    Caizzi, Emanuela
    Mazziotta, Francesco
    Alunni, Giulia
    Di Bona, Eros
    Crugnola, Monica
    Rossi, Marianna
    Consoli, Ugo
    Fontanelli, Giulia
    Greco, Giuseppina
    Nadali, Gianpaolo
    Rotondo, Francesco
    Todisco, Elisabetta
    Bigazzi, Catia
    Capochiani, Enrico
    Molteni, Alfredo
    Bernardi, Massimo
    Fumagalli, Monica
    Rondoni, Michela
    Scappini, Barbara
    Ermacora, Anna
    Simonetti, Federico
    Gottardi, Michele
    Deliliers, Daniela Lambertenghi
    Michieli, Mariagrazia
    Basilico, Claudia
    Galeone, Carlotta
    Pelucchi, Claudio
    Rossi, Giuseppe
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 447 - 455
  • [37] Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China
    Yu, Guopan
    Yin, Zhao
    Xu, Dan
    Jiang, Xuejie
    Ye, Jieyu
    Zhang, Yu
    BLOOD, 2022, 140 : 11740 - 11740
  • [38] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Zhu, Li-xia
    Chen, Rong-rong
    Wang, Lu-lu
    Sun, Jia-nai
    Zhou, De
    Li, Li
    Qian, Jie-jing
    Zhang, Yi
    Tong, Hong-yan
    Yu, Wen-juan
    Meng, Hai-tao
    Mai, Wen-yuan
    Xie, Wan-zhuo
    Jin, Jie
    Ye, Xiu-jin
    Zhu, Hong-hu
    SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 7031 - 7038
  • [39] A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia
    Li-xia Zhu
    Rong-rong Chen
    Lu-lu Wang
    Jia-nai Sun
    De Zhou
    Li Li
    Jie-jing qian
    Yi Zhang
    Hong-yan Tong
    Wen-juan Yu
    Hai-tao Meng
    Wen-yuan Mai
    Wan-zhuo Xie
    Jie Jin
    Xiu-jin Ye
    Hong-hu Zhu
    Supportive Care in Cancer, 2022, 30 : 7031 - 7038
  • [40] Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
    Patel, Kishan K.
    Zeidan, Amer M.
    Shallis, Rory M.
    Prebet, Thomas
    Podoltsev, Nikolai
    Huntington, Scott F.
    BLOOD ADVANCES, 2021, 5 (04) : 994 - 1002
12345